New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 23, 2014
08:11 EDTCVMCEL-SCI cleared to begin patient enrollment
CEL-SCI announced that Turkey's Ministry of Health had cleared the company to begin patient enrollment in CEL-SCI's global pivotal Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine. The news that Turkey has the 16th country to participate in the world's largest Phase III head and neck cancer trial of the firm's Leukocyte Interleukin, Injection follows last week's news that Sri Lanka's Ministry of Health had also cleared the company to commence patient enrollment in Sri Lanka. Similar clearances to conduct the Phase III study in the UK and Austria were announced in previous weeks and though it has becoming increasingly clear that CEL-SCI's expansion of the trial is finally going as planned, the valuation and share prices have yet to see a real impact.
News For CVM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 26, 2015
09:03 EDTCVMCEL-SCI receives regulatory clearance to expand Phase III trial
CEL-SCI Corporation announced the Romanian Ministry of Health has cleared the company to begin patient enrollment and conduct its Phase III head and neck cancer trial of its investigational cancer immunotherapy treatment Multikinein Romania. The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. The objective of the study is to demonstrate a statistically significant improvement in the overall survival of enrolled patients who are treated with the Multikine treatment regimen plus Standard of Care vs. subjects who are treated with SOC only.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use